PVLA — Palvella Therapeutics Share News
0.000.00%
Last trade - 00:00Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs
Brief: Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas
Brief: Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America
U.S. STOCKS ON THE MOVE-Qnity, J.M. Smucker, Vistra
Palvella Therapeutics extends surge after upsized $200 mln equity raise
Brief: Palvella Therapeutics Announces Pricing Of Upsized Public Offering
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP
Brief: Palvella Therapeutics Announces Proposed Public Offering
U.S. STOCKS ON THE MOVE-Domino's Pizza, FactSet, IBM
U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSet
U.S. STOCKS ON THE MOVE-Advanced Micro Devices, Constellation Energy, NRG Energy
Palvella jumps after rare disease treatment shows improvement in late-stage study
Brief: Palvella Therapeutics Announces Positive Topline Results From Phase 3 Selva Clinical Study Of Qtorin™
Brief: Palvella Therapeutics Provides Corporate Update And 2026 Outlook
Palvella Therapeutics climbs after Truist raises PT